EUVIMEDEUVIMED entdecken
Crossref

Engineered Platelet for In Situ Natural Killer Cell Activation to Inhibit Tumor Recurrence

Yueyang Deng, Caixia Tan, Shuguang Huang, Zhanwei Zhou, Xinping Luo, Xue Yang, Minjie Sun iD

Nano Letters · 2024

DOI: 10.1021/acs.nanolett.4c02316 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nano Letters, 2024. Verfasst von Yueyang Deng und 6 weiteren Autor:innen. Beteiligte Einrichtung: NMPA Key Laboratory for Research and Evaluation of Pharmaceutical Preparations and Excipients, State Key Laboratory of Natural Medicines, Department …. Hauptthemen laut MEDLINE: Killer Cells, Natural, Blood Platelets, Interleukin-15. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Jiangsu Provincial Key Research and Development Program, Natural Science Foundation of Jiangsu Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Natural killer (NK) cells offer profound advantages against tumor recurrence due to their unique immunological behavior. NK cell therapies associated with the antibody-dependent cell-mediated cytotoxicity (ADCC) effect have made remarkable progress while being limited by insufficient antibody binding and the exhausted state of NK cells in the postsurgical immunosuppressive microenvironment. Leveraging the adherence of PLT to tumor cells, we developed an exogenously implanted platelet (PLT)-based NK cell-driven system (PLT-IgG-IL15) to improve the identifiability of residual tumors with IgG antibody labeling for NK cells catching and engaging, which consequently restored the ADCC effect and promoted the recovery of their killing function. Furthermore, interleukin-15 (IL-15) participated in the augmentation of NK cell function. Collectively, PLT-IgG-IL15 served as an NK cell tumor cell engager as well as an NK cell charger, achieving a

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Killer Cells, NaturalBlood PlateletsInterleukin-15AnimalsMiceHumansCell Line, TumorNeoplasm Recurrence, LocalAntibody-Dependent Cell CytotoxicityImmunoglobulin GLymphocyte ActivationTumor Microenvironment

Stichwörter der Autor:innen

ADCC effectIL-15engineered plateletimmunotherapytumor recurrence

Substanzen

Interleukin-15Immunoglobulin G

Autor:innen und Institutionen

  • NMPA Key Laboratory for Research and Evaluation of Pharmaceutical Preparations and Excipients, State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, Chi…

ORCID-Profile: Minjie Sun

Förderung

  • Jiangsu Provincial Key Research and Development Program
  • Natural Science Foundation of Jiangsu Province
  • National Natural Science Foundation of China

Zitieren

APA

Deng, Y., Tan, C., Huang, S., Zhou, Z., Luo, X., Yang, X., & Sun, M. (2024). Engineered Platelet for In Situ Natural Killer Cell Activation to Inhibit Tumor Recurrence. Nano Letters. https://doi.org/10.1021/acs.nanolett.4c02316

Vancouver

Deng Y, Tan C, Huang S, Zhou Z, Luo X, Yang X, et al. Engineered Platelet for In Situ Natural Killer Cell Activation to Inhibit Tumor Recurrence. Nano Letters. 2024. doi:10.1021/acs.nanolett.4c02316

BibTeX
@article{Deng2024,
  author = {Deng, Yueyang and Tan, Caixia and Huang, Shuguang and Zhou, Zhanwei and Luo, Xinping and Yang, Xue and Sun, Minjie},
  title = {Engineered Platelet for In Situ Natural Killer Cell Activation to Inhibit Tumor Recurrence},
  journal = {Nano Letters},
  year = {2024},
  doi = {10.1021/acs.nanolett.4c02316}
}
Kostenlos starten →